CLIA Mycoplasma IgM
The chemiluminescence assay is intended for the diagnosis of Mycolasma pneumoniae infection using IgM antibodies in human serum or plasma in the general population.
New
The chemiluminescence assay is intended for the diagnosis of Mycolasma pneumoniae infection using IgM antibodies in human serum or plasma in the general population.
| Catalog Number: | CL-MyM100 |
|---|---|
| Size: | 100 tests |
| Regulatory status: | CE IVD |
| Clinical topic: | Infectious Diseases |
| Diagnostic panel: |
COVID-19 Respiratory Diseases |
Mycoplasma pneumoniae is a primary pathogenic agent of the human respiratory tract. It causes pneumonia accompanied by fever, nausea, ague, cough, and fatigue. The disease is prolonged but well curable with antibiotics. The pathogen is airborne, spread especially in dense gatherings of children, particularly during spring and autumn months.
| Assay time | 30 min |
| Assay stability | 30 days on board stability / In use stability until the expiration date at storage temperature 2-8 °C |
| Sample matrix | Serum, Plasma |
| Sample volume | 10 µL |
| Measuring range | 2–160 U/ml |
| Assay/kit content | Reagent Cartridge with specific reagents for the assay, magnetic particles, calibrators |
| Complementary products | Wash buffer, Anchor® Tips, Stackable cuvettes, Trigger solutions |
| Note | The kits are CE-IVD certified and intended for professional use. |